6.
Moore J, Ahmed H, Jia J, Akondy R, Ahmed R, Antia R
. What Controls the Acute Viral Infection Following Yellow Fever Vaccination?. Bull Math Biol. 2017; 80(1):46-63.
PMC: 5766411.
DOI: 10.1007/s11538-017-0365-3.
View
7.
Suhrbier A, Linn M
. Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol. 2003; 24(4):165-8.
DOI: 10.1016/s1471-4906(03)00065-6.
View
8.
Schieffelin J, Costin J, Nicholson C, Orgeron N, Fontaine K, Isern S
. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J. 2010; 7:28.
PMC: 2829534.
DOI: 10.1186/1743-422X-7-28.
View
9.
Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T
. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018; 379(4):327-340.
DOI: 10.1056/NEJMoa1800820.
View
10.
Plotkin S
. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17(7):1055-65.
PMC: 2897268.
DOI: 10.1128/CVI.00131-10.
View
11.
Goncalvez A, Engle R, St Claire M, Purcell R, Lai C
. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007; 104(22):9422-7.
PMC: 1868655.
DOI: 10.1073/pnas.0703498104.
View
12.
Horstick O, Martinez E, Guzman M, San Martin J, Runge Ranzinger S
. WHO dengue case classification 2009 and its usefulness in practice: an expert consensus in the Americas. Pathog Glob Health. 2015; 109(1):19-25.
PMC: 4445290.
DOI: 10.1179/2047773215Y.0000000003.
View
13.
Kliks S, Nimmanitya S, Nisalak A, Burke D
. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988; 38(2):411-9.
DOI: 10.4269/ajtmh.1988.38.411.
View
14.
Rodenhuis-Zybert I, van der Schaar H, da Silva Voorham J, van der Ende-Metselaar H, Lei H, Wilschut J
. Immature dengue virus: a veiled pathogen?. PLoS Pathog. 2010; 6(1):e1000718.
PMC: 2798752.
DOI: 10.1371/journal.ppat.1000718.
View
15.
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W
. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745-8.
PMC: 3837288.
DOI: 10.1126/science.1185181.
View
16.
Vaughn D, Green S, Kalayanarooj S, Innis B, Nimmannitya S, Suntayakorn S
. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 1999; 181(1):2-9.
DOI: 10.1086/315215.
View
17.
Penaloza-MacMaster P, Barber D, Wherry E, Provine N, Teigler J, Parenteau L
. Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection. Science. 2015; 347(6219):278-82.
PMC: 4382081.
DOI: 10.1126/science.aaa2148.
View
18.
Simmons C, Chau T, Thuy T, Tuan N, Hoang D, Thien N
. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis. 2007; 196(3):416-24.
PMC: 4333207.
DOI: 10.1086/519170.
View
19.
Laoprasopwattana K, Libraty D, Endy T, Nisalak A, Chunsuttiwat S, Vaughn D
. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis. 2005; 192(3):510-9.
DOI: 10.1086/431520.
View
20.
Ferguson N, Rodriguez-Barraquer I, Dorigatti I, Mier-Y-Teran-Romero L, Laydon D, Cummings D
. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science. 2016; 353(6303):1033-1036.
PMC: 5268127.
DOI: 10.1126/science.aaf9590.
View